HIV Research for Prevention (HIVR4P)

aidsmap news from HIV R4P 2014

• Strategies to improve male partner involvement in microbicide research needed

  Microbicides
  Lesley Odendal | 17 December 2014

  Vaginal microbicides were partially developed in response to power differentials within sexual relationships and gender norms that make it difficult for women to negotiate other forms of HIV protection, as it can be ...

• Positive response to 'gift tokens for undetectable viral load' trial

  Adherence
  Gus Cairns | 24 November 2014

  A US study presented at last month’s HIV Research for Prevention conference found generally positive responses among a selection of participants and clinic staff to a trial that used $70 gift tokens as ...

• Groundbreaking HIV vaccine's effects were real – and could be made to work better

  The search for an HIV prevention vaccine
  Gus Cairns | 13 November 2014

  Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They ...

• What are the barriers that could stop HIV treatment becoming HIV prevention?

  Undetectable viral load and treatment as prevention
  Gus Cairns | 12 November 2014

  One of the key strategies involved in trying to bring an end to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral therapy (ART), to the point where ...

• Misunderstanding of questions regarding anal sex in microbicide HIV prevention trial

  Microbicides
  Lesley Odendal | 10 November 2014

  There was widespread misunderstanding and misinterpretation of questions about anal sex being asked of participants in the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial, according to findings of a ...

• Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex

  PrEP
  Gus Cairns | 01 November 2014

  A phase one dose-finding and safety study in humans of TMC278 LA, a long-acting, injectable formation of the antiretroviral (ARV) drug rilpivirine, found that a single 1200-mg dose could produce sustained ...

• Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

  PrEP
  Gus Cairns | 30 October 2014

  Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK744) that will be taken into efficacy trials to see if it can be used for pre-exposure prophylaxis ...

• Tenofovir gel use associated with lower HSV-2 risk in women

  Microbicides
  Lesley Odendal | 30 October 2014

  The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by 46% (aIRR:0.54, 95%CI:0.30-0.97, p = 0.038) among women who regularly used the vaginal gel containing tenofovir, according to a secondary ...

• Research for Prevention conference opens with real hope for an HIV vaccine

  The search for an HIV prevention vaccine
  Gus Cairns | 29 October 2014

  “There’s only one Berlin patient still. But by this time next year he will at least be joined by 40-50 Portland monkeys.” This was vaccine researcher Louis Picker, summarising in quotable form why ...